Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients

被引:0
作者
Tan, Wen Rui [1 ,2 ]
Irie, Kei [2 ]
Mcintire, Carter [3 ]
Torres, Julie Luna [3 ]
Jones, Rhonda [4 ]
Gibson, Abigayle [4 ]
Mizuno, Tomoyuki [2 ,5 ]
Girdwood, Sonya Tang [2 ,3 ,5 ]
机构
[1] Univ Cincinnati, Coll Med, Dept Pharmacol & Syst Physiol, Cincinnati, OH 45267 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Translat & Clin Pharmacol, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Hosp Med, Cincinnati, OH USA
[4] Cincinnati Childrens Hosp Med Ctr, Crit Care Med, Cincinnati, OH USA
[5] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
关键词
modeling and simulation; population pharmacokinetic; beta-lactam; SURGERY;
D O I
10.1128/aac.01227-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Piperacillin/tazobactam (PTZ) is frequently prescribed during the perioperative period as prophylaxis in critically ill patients. Current international guidelines recommend that the pediatric intraoperative dosing regimen for PTZ be 90-112.5 mg/kg (80-100 mg/kg as piperacillin [PIP]) administered every 2 hours (Q2H). Concerns have been raised not only about the risk of nephrotoxicity due to elevated PIP exposure but also regarding the practicality of adhering to a 2-h dosing interval in clinical settings. To address these concerns, we employed population pharmacokinetic (PK) modeling and simulation approaches to optimize PTZ dosing regimens in pediatric intraoperative patients. PIP plasma concentration data were obtained from 34 patients using an opportunistic sampling strategy. A two-compartment model was found to adequately describe the PK data. Creatinine clearance was identified as a significant covariate on clearance. The inclusion of inter-occasion variability significantly improved model fit. Simulations across body weights of 10-70 kg and creatinine clearance of 20-130 mL/min/1.73 m(2) demonstrated that 6-15 mg/kg Q2H, or a 10 mg/kg loading dose followed by 1.0-2.75 mg/kg/h continuous infusion would achieve free PIP concentrations being above the minimum inhibitory concentration (MIC) for 100% of the dosing interval (100% fT >1x MIC). For achieving 100% fT >4x MIC, 25-55 mg/kg Q2H or a 20 mg/kg loading dose followed by 3.25-9.25 mg/kg/h continuous infusion was derived. The model-informed simulations indicated that both lower Q2H doses and continuous infusion methods are clinically viable options and potentially resolve current clinical challenges during intraoperative dosing.
引用
收藏
页数:13
相关论文
共 27 条
[1]   Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically III Patients [J].
Alobaid, Abdulaziz S. ;
Wallis, Steven C. ;
Jarrett, Paul ;
Starr, Therese ;
Stuart, Janine ;
Lassig-Smith, Melissa ;
Mejia, Jenny Lisette Ordonez ;
Roberts, Michael S. ;
Roger, Claire ;
Udy, Andrew A. ;
Lipman, Jeffrey ;
Roberts, Jason A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (03)
[2]   Mechanism-based concepts of size and maturity in pharmacokinetics [J].
Anderson, B. J. ;
Holford, N. H. G. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :303-332
[3]   Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically III Children with Normal and Augmented Renal Clearance [J].
Beranger, Agathe ;
Benaboud, Sihem ;
Urien, Saik ;
Moulin, Florence ;
Bille, Emmanuelle ;
Lesage, Fabrice ;
Zheng, Yi ;
Genuini, Mathieu ;
Gana, Ines ;
Renolleau, Sylvain ;
Hirt, Deborah ;
Treluyer, Jean-Marc ;
Oualha, Mehdi .
CLINICAL PHARMACOKINETICS, 2019, 58 (02) :223-233
[4]  
Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI [10.2146/ajhp120568, 10.1089/sur.2013.9999]
[5]   Nonlinear pharmacokinetics of piperacillin in healthy volunteers - implications for optimal dosage regimens [J].
Bulitta, Juergen B. ;
Kinzig, Martina ;
Jakob, Verena ;
Holzgrabe, Ulrike ;
Soergel, Fritz ;
Holford, Nicholas H. G. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) :682-693
[6]   Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance [J].
Byon, W. ;
Smith, M. K. ;
Chan, P. ;
Tortorici, M. A. ;
Riley, S. ;
Dai, H. ;
Dong, J. ;
Ruiz-Garcia, A. ;
Sweeney, K. ;
Cronenberger, C. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (07)
[7]   A Narrative Review on Perioperative Pain Management Strategies in Enhanced Recovery Pathways-The Past, Present and Future [J].
Chen, Qiliang ;
Chen, Erdong ;
Qian, Xiang .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
[8]   Dose optimization of piperacillin/tazobactam in critically ill children [J].
De Cock, Pieter A. J. G. ;
van Dijkman, Sven C. ;
de Jaeger, Annick ;
Willems, Jef ;
Carlier, Mieke ;
Verstraete, Alain G. ;
Delanghe, Joris R. ;
Robays, Hugo ;
Vande Walle, Johan ;
Della Pasqua, Oscar E. ;
De Paepe, Peter .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) :2002-2011
[9]   Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial [J].
Elmokadem, Ahmed ;
Riggs, Matthew M. ;
Baron, Kyle T. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (12) :883-893
[10]  
Food and Drug Administration(FDA), 2022, PIPERACILLIN SODIUM